GlassScriptPhysician profile
Ashley Klisz
NPI 1225421373
$18,778.64
in general payments reported to CMS, 2019-2025
67 companies · $2,771 in 2025
The $2,771 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,427 · 2022: $2,189 · 2023: $5,092 · 2024: $7,300 · 2025: $2,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $343 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $270 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,388.60 |
| Travel and Lodging | $343.10 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $269.78 |
| Education | $160.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,360.28 | 2021-2025 | |
| Emd Serono, INC. | $1,248.96 | 2023-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,054.45 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Ucb, INC. | $1,015.06 | 2021-2025 | Nayzilam, Rystiggo, Briviact |
| Nalu Medical, INC. | $978.38 | 2022 | |
| Nevro Corp. | $976.68 | 2022-2023 | Senza |
| Abbvie INC. | $974.41 | 2022-2025 | |
| Neurelis, INC. | $616.88 | 2021-2025 | Valtoco |
| Genzyme Corporation | $573.89 | 2023-2025 | |
| Pfizer INC. | $513.98 | 2021-2025 | |
| Biogen, INC. | $511.37 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Celgene Corporation | $496.19 | 2021-2025 | Zeposia |
| Alnylam Pharmaceuticals INC. | $486.15 | 2021-2025 | Onpattro |
| Lundbeck LLC | $459.02 | 2021-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $439.65 | 2023-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $438.34 | 2023-2025 | Ingrezza, Ongentys |
| Axsome Therapeutics, INC. | $354.28 | 2024-2025 | Symbravo, Sunosi |
| Lilly USA, LLC | $333.67 | 2023-2025 | Emgality, Reyvow, Amyvid |
| Otsuka America Pharmaceutical, INC. | $330.45 | 2023-2025 | Nuedexta, Rexulti |
| Argenx US, INC. | $315.64 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $312.16 | 2023-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $269.37 | 2023-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $265.62 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.96 | 2024-2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $231.10 | 2023-2025 | Wainua, Andexxa, Evusheld |
| Amgen INC. | $203.97 | 2023-2025 | Uplizna, Aimovig |
| Eisai INC. | $191.18 | 2024-2025 | |
| Csl Behring | $185.98 | 2022-2025 | Hizentra |
| Sumitomo Pharma America, INC. | $172.55 | 2023-2024 | Aptiom |
| Genentech USA, INC. | $170.92 | 2023-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Janssen Pharmaceuticals, INC | $165.93 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $161.01 | 2021 | |
| Kyowa Kirin, INC. | $156.60 | 2022-2024 | Nourianz |
| Scilex Pharmaceuticals INC. | $143.85 | 2023-2024 | Ztlido |
| Ani Pharmaceuticals, INC. | $124.26 | 2023-2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $116.23 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $96.82 | 2023-2024 | Rytary, Crexont |
| E.R. Squibb & Sons, L.L.C. | $92.33 | 2021-2024 | Zeposia |
| Grt US Holding, INC. | $91.03 | 2021-2022 | |
| Acorda Therapeutics, INC | $79.08 | 2023-2024 | Inbrija |
| Vanda Pharmaceuticals INC. | $78.24 | 2025 | Ponvory |
| Catalyst Pharmaceuticals, INC. | $68.40 | 2024 | |
| Cycle Pharmaceuticals INC | $54.00 | 2024-2025 | Tascenso Odt |
| Octapharma USA, INC. | $51.93 | 2024-2025 | Panzyga |
| Sunovion Pharmaceuticals INC. | $46.62 | 2022 | |
| Horizon Therapeutics Plc | $45.75 | 2022-2023 | Uplizna |
| Azurity Pharmaceuticals, INC. | $44.33 | 2023-2024 | Horizant, Horizant |
| Allergan, INC. | $38.66 | 2021 | |
| Mallinckrodt Hospital Products INC. | $36.76 | 2021 | |
| Hospira, INC. | $31.49 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $30.42 | 2025 | Lumryz |
| Averitas Pharma INC. | $26.49 | 2024 | Qutenza |
| Grifols USA, LLC | $24.22 | 2023 | Gamunex-C |
| Tanabe Pharma America, INC. | $22.68 | 2024 | |
| Validus Pharmaceuticals LLC | $22.66 | 2023 | Equetro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.55 | 2024 | Rexulti |
| Harmony Biosciences LLC | $20.15 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.60 | 2022 | |
| Corium, LLC | $18.86 | 2023 | Adlarity |
| Cala Health, INC. | $17.85 | 2023 | Cala Trio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.78 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.65 | 2023 | Keveyis |
| Livanova USA, INC. | $15.52 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.49 | 2021 | |
| Owp Pharmaceuticals, INC. | $15.29 | 2023 | Lamotrigine, Subvenite |
| Avanir Pharmaceuticals, INC. | $11.80 | 2021 | |
| Aucta Pharmaceuticals, INC. | $10.77 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Klisz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.